These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 18990549

  • 1. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
    Hascoet JM, Fagnani F, Charlemagne A, Vieux R, Rozé JC, Bendjenana H.
    Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
    [Abstract] [Full Text] [Related]

  • 2. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE, Mahle WT.
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [Abstract] [Full Text] [Related]

  • 3. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
    Nuijten M, Lebmeier M, Wittenberg W.
    J Med Econ; 2009 Dec; 12(4):291-300. PubMed ID: 19811111
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
    Committee on Infectious Diseases.
    Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
    [Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of palivizumab in children with congenital heart disease in Germany.
    Nuijten M, Lebmeier M, Wittenberg W.
    J Med Econ; 2009 Dec; 12(4):301-8. PubMed ID: 19811110
    [Abstract] [Full Text] [Related]

  • 13. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC.
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [Abstract] [Full Text] [Related]

  • 14. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C, Kauf TL, Saidi AS, Winterstein AG.
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [Abstract] [Full Text] [Related]

  • 16. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J.
    Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
    [Abstract] [Full Text] [Related]

  • 17. [Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France].
    Pinquier D, Gouyon JB, Fauroux B, Mons F, Vicaut E, Bendjenana H, Rouffiac E, Marret S, Aujard Y.
    Arch Pediatr; 2009 Nov; 16(11):1443-52. PubMed ID: 19767182
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW.
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [Abstract] [Full Text] [Related]

  • 19. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
    McCormick J, Tubman R.
    Pediatr Pulmonol; 2002 Oct; 34(4):262-6. PubMed ID: 12205567
    [Abstract] [Full Text] [Related]

  • 20. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
    Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network.
    Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.